NL-OMON24089
Recruiting
Not Applicable
Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapy
etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital0 sites42 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- cancer, capecitabine, phase I, chronotherapy, biomarker, pharmacology, kanker, chronotherapie, fase I
- Sponsor
- etherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
- Enrollment
- 42
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histological or cytological proof of cancer
- •2\. Patient who might benefit from treatment with capecitabine, e.g. colon, breast, pancreatic and gastric cancer, ACUP;
Exclusion Criteria
- •1\. Dihydropyrimidine dehydrogenase (DPD) deficiency as assessed on the basis of DPYD IVS14\+1G\>A (DPYD\*2A) and 2846A\>T mutation analysis;
- •2\. Women who are pregnant or breast feeding;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Phase I pharmacological study of continuous and intermittent chronomodulated capecitabine therapycancermalignancies10027655NL-OMON40756Antoni van Leeuwenhoek Ziekenhuis42
Completed
Not Applicable
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150
Completed
Not Applicable
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.Blooddiseaseleukemia/lymophoma10047954NL-OMON35094Calistoga Pharmaceuticals Inc.15
Completed
Not Applicable
Prospective pharmacokinetic study of continuous-infusional 5-FJPRN-UMIN000035580Keio University60
Completed
Phase 1
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersN/AOther -ACTRN12605000782639Epitan Limited6